Lauréate du concours i-Nov 2025 et bénéficiaire de fonds européenFeder, Priothera est en train de boucler sa levée de fonds pour accélérer le développement de son candidat médicament dans l’objectif d’en faire un standard dans le traitement des cancers du sang. La licorne, basée à Saint-Louis dans le Haut-Rhin, est en phase clinique avancée en … Read more
Transmutex develops technology for an accelerator-driven nuclear reactor that can transmute long-lived transuranic elements and problematic fission products from the traditional uranium fuel cycle. This includes transuranic nuclides such as plutonium, neptunium, americium, and curium, as well as transmuting long-lived fission products like iodine-129, technetium-99, and selenium-79. Studies in Switzerland and Germany show that this … Read more
Distalmotion announces that it completed the first US sale and delivery of the DEXTER Robotic Surgery System to Memorial Hermann Health System in Houston, Texas in early February. This milestone marks a significant step toward expanding access to robotic surgery in the United States. Distalmotion, a MedTech company with more than 1,500 surgical cases completed … Read more
Joining an esteemed panel at the Longwood Fund Healthcare Leaders meeting, Lynn Durham discusses the need for patient centric drug development, specifically in the context of neurodevelopmental disorders https://stalicla.com/assets/new/img/news/articles/Longwood_Fund_annual_meeting_horizontal.jpg See full text Follow us on
Geneva, Switzerland – June 30, 2025 – STALICLA SA, a Geneva-based clinical-stage biotech company pioneering precision medicine for neurodevelopmental and neuropsychiatric disorders, today announced the successful closing of a CHF 2 million financing led by Addex Therapeutics. This financing will sustain operations and program development in neurodevelopmental disorders as Stalicla prepares for its upcoming Series C … Read more
daniel bertholet
Copyright © 2024